Highest-materiality recent filing
Jaguar Health declares Series R preferred dividend, amends royalty and note obligations
Board declared special one-time dividend of one Series R Convertible Preferred share per common share; record date Oct 13, 2026, payment date Oct 15, 2026.
Jaguar Health issues 481,584 shares to Streeterville to cut 2021 Note by $3.4 million
Jaguar Health entered Sept. 25, 2026 exchange agreements with Streeterville Capital to issue 481,584 common shares for a $3,400,000 reduction of its 2021 Note.
2021 Note exchange: issued 182,091 shares to Streeterville for a $1,678,320 reduction of the secured note originally issued Jan. 19, 2021 with a $6,220,812.50 principal.
Jaguar Health issues 547,898 shares to cut $5.05M of 2025 Streeterville note
Exchanged 547,898 common shares for $5,049,909 reduction in $10.81M secured note to Streeterville Capital.
Jaguar Health effects 1-for-15 reverse stock split, eliminates 14 preferred series
Reverse stock split effective Sept 17, 2026; post-split common shares outstanding approx 520,088.
Jaguar Health issues equity to retire debt and acquire Napo Therapeutics minority stake
Issued 557,377 shares to Lincoln Alternative to retire 6% convertible note with $175,016.36 balance on Sept 11, 2026.
Jaguar Health announces 1-for-15 reverse stock split effective Sept 17, 2026
1-for-15 reverse split effective 12:01 am ET Sept 17, 2026; trading begins split-adjusted on Nasdaq under JAGX.
Jaguar Health special meeting lacks quorum; no vote taken, meeting not reconvened
Special meeting of stockholders called on September 4, 2026, failed due to insufficient quorum.
Jaguar Health Q2 2026 revenue down 59% YoY; net loss widens to $12.7M
Total net revenue $1.225M vs $2.979M in Q2 2025 (-59%); product revenue down 60% to $1.18M.
New agreement with Alivus Life Sciences for manufacture of crofelemer for Mytesi and other products.
Jaguar Health completes conversion of Series O Preferred Stock; shares outstanding now 4.86M
On June 25, 2026, all outstanding Series O Preferred Stock and shares issuable upon Eligible Warrants converted into common stock at 3.209:1 ratio.
Jaguar Health converts Series O Preferred Stock to common at 3.209:1, pays $2.68 for fractions
Each share of Series O Preferred Stock converted into 3.209 common shares on June 25, 2026; fractional shares paid in cash at $2.68/share.
Jaguar Health explores strategic alternatives for crofelemer rare disease program
Board initiates process to explore strategic alternatives including M&A, partnerships, licensing; no guarantee of transaction.
Jaguar Health explores strategic alternatives; crofelemer NDA targeted for rare intestinal failure
Board initiated process to evaluate strategic alternatives including M&A, partnerships, and licensing to maximize shareholder value.
Royalty amendments: Uptown and Streeterville minimum monthly payment increased to $750k, effective Oct 1, 2026.
Jaguar Health secures up to $40M equity line and $2M preferred stock financing
ELOC agreement provides up to $40M of common stock purchases; floor price set at $1.10 per share.
John Micek III elected Class II director with 3,967,085 for, 240,944 withheld.
Jaguar Health issues 64,668 common shares for Series Q Preferred; annual meeting adjourned to June 8
Issued 31,958 and 32,710 common shares to Streeterville on May 26 and June 1, 2026, respectively, in exchange for 3.72 and 4.2 Series Q Preferred shares.
Jaguar Health regains Nasdaq Bid Price compliance; monitoring until May 2027
Formal notice from Nasdaq on May 26, 2026: Jaguar complies with Bid Price Rule (closing bid ≥$1/sh).
Issued 54,222 common shares to Streeterville in exchange for 7.96 shares of Series Q Preferred Stock.
Jaguar Health Q1 revenue up 816% to $20.3M on $19M license deal; net loss narrows to $7.0M
Total revenue $20.3M (816% YoY increase) driven by $19.1M license revenue from Woodward/Future Pak deal.
Jaguar Health exchanges $22.7M in royalty interests for Series Q Preferred Stock
Uptown Capital: $12.5M royalty reduction for 500 Series Q shares.
Jaguar Health gets Nasdaq extension to May 18 for bid-price compliance; delisting risk remains
Received Nasdaq Staff notice on May 1, 2026 for non-compliance with 500,000 publicly held shares requirement.
Post 1-for-35 reverse stock split on April 30, 2026, publicly held shares are ~401,226, below 500,000 minimum.
Jaguar Health cures Nasdaq publicly held shares deficiency via warrant exercises after reverse split
Received Nasdaq notice on May 1, 2026 for non-compliance with minimum 500,000 publicly held shares after 1-for-35 reverse split on April 30.
Jaguar Health granted Nasdaq extension to May 15, 2026; announces 1-for-35 reverse stock split
Nasdaq Panel grants extension until May 15, 2026 to demonstrate compliance with $1.00 minimum bid price rule.
Jaguar Health stockholders approve authorized share increase and two reverse stock split proposals
Authorized common stock increased from 298M to 500M shares; total authorized shares from 352M to 554M.
Jaguar Health regains Nasdaq equity compliance after $27M in capital events
Stockholders' deficit was $18.7M at Dec 31, 2025, below Nasdaq's $2.5M minimum.
Net revenue FY2025 $11.5M (-1.5% YoY); Q4 2025 net revenue $3.2M (+5% QoQ, -8% YoY).
Jaguar Health postpones royalty payments, extends notes, terminates 48,211 warrants
Royalty payment start postponed to July 1, 2026; Uptown amount reduced to $11,125,282.54, Streeterville to $12,428,782.20.
Jaguar Health receives Nasdaq delisting notice for bid price; plans to appeal
Nasdaq notice on March 5, 2026: bid price below $1.00 for 30 consecutive business days.
Jaguar Health files Series O Preferred Stock certificate for special dividend payable March 4
Filed Certificate of Designation for 1,557,000 shares of Series O Convertible Preferred Stock.
Jaguar Health declared a one-time special stock dividend of Series O Preferred Stock on February 18, 2026.
Jaguar Health issues ~11.8M pre-funded warrants to reduce $2.04M in royalties and preferred stock
Reduced $1.19M Iliad royalty and $0.85M Streeterville royalty by issuing 1.55M and 1.11M pre-funded warrants.
Exclusive license to Future Pak for Mytesi (HIV/AIDS diarrhea) and Canalevia-CA1 (chemotherapy-induced diarrhea in dogs) in U.S.
Jaguar Health issues $350K in 6% notes with warrants; corrects prior filing dates
Issued $350,000 aggregate principal amount of 6% unsecured promissory notes to two accredited investors.
Jaguar Health issues $350K in 6% notes and warrants for 350K shares at $1.00
Issued $350,000 aggregate principal amount of unsecured promissory notes to two accredited investors.
Jaguar Health closes $350K private placement of 6% notes and warrants for working capital
Issued $350K aggregate principal of 6% unsecured promissory notes to accredited investors on Jan 6, 2026.
Jaguar Health swaps 91 Series M Preferred shares for 440K common shares and 1.6M pre-funded warrants
On Dec 9, exchanged 75 Series M Preferred for 400K common shares and warrant for 1,304,545 shares at $0.001.
JAGX stockholders approve three proposals; crofelemer MVID trial shows up to 37% PS reduction
Stockholders approved proposal to issue shares upon exchange/redemption of Series N Preferred Stock (1,032,716 For, 73,065 Against).
Jaguar Health amends $36M royalty obligations, extends debt, exchanges preferred for common
Royalty Interest amendments set minimum monthly payment of $750,000 per $12M royalty from April 1, 2026.
Jaguar Health issues $10.81M secured note to Streeterville Capital; $8M held as collateral
Net proceeds of $10M after $800K OID and $10K transaction expenses; interest 8% p.a., maturity 36 months.
Jaguar Health issues 286,532 shares to reduce royalty interest by $600,000
Issued 286,532 common shares in exchange for $600,000 reduction in outstanding royalty interest balance.
Jaguar Health raises $1M via PIPE: 161,583 shares + 479,442 pre-funded warrants at $1.56/share
Issued 161,583 common shares and 479,442 pre-funded warrants to Brown Stone Capital at $1.56/share (warrant price $1.5599); total proceeds $1M.
Jaguar Health raises $2.38M via Series N Perpetual Preferred Stock PIPE
Issued ~951 Series N Preferred shares at $2,500 stated value each for aggregate proceeds of $2.38M.
Jaguar Health: Crofelemer cuts TPN needs in MVID/SBS; FDA outlines sNDA path for breast cancer
All 7 proposals approved at Aug 19 annual meeting; directors elected, stock plan amended, share issuances authorized.
Jaguar Health extends ATM manager Lucid's term to Dec 31, 2025
Sixth ATM Amendment extends Lucid Capital Markets' service as manager from June 30 to Dec 31, 2025.
Jaguar Health cuts royalty debt by $6.5M, issues Series M preferred to Iliad and Streeterville
Issued 170 shares of Series M Preferred to Iliad for $4.25M reduction in October 2020 royalty interest.
Company entered Exchange Agreements with certain investors to replace ~$2.57M of 6% convertible notes originally due June 30, 2025; new maturity January 30, 2026.
Jaguar Health raises ~$1.5M in registered direct offering with warrants
Issued 246,306 shares at $6.09/share; gross proceeds ~$1.5M.
Mr. Greg J. Divis notified the Board of Directors (the “Board”) of Jaguar Health, Inc. (the “Company”) of his intention to resign as a member of the Board, effective as of July 1, 2022.
the Board, by resolution as contemplated in the Company’s bylaws, appointed Dr. Anula Jayasuriya to fill the vacancy created by Mr. Divis’s resignation and serve as Class III director of the Company
Max materiality 0.95 · Median 0.65 · Most common event other_material